Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".

(a) Cohort of Multiple Myeloma patients treated with DVd (Daratumumab + Bortezomib + Dexamethasone): OS in the subgroup of "Lenalidomide-refractory patients" (70.6% of patients). The last treatment received before the DVd regimen was Carfilzomib-Lenalidomide-Dexamethasone (KRd) (39.6%), Lenalidomide-Dexamethasone (Rd) (39.6%), Elotuzumab-Lenalidomide-Dexamethasone (EloRd) (14.6%) and Ixazomib-Lenalidomide-Dexamethasone (IxaRd) (6.2%). (range 1-34)</td></tr></tbody></table> ht 1 Hgb: hemoglobin; LDH: lactate dehydrogenase; 2M: 2microglobulin; DVd: Daratumumab-Bortezomib-Dexamethasone; KRd: Carfilzomib-Lenalidomide-Dexamethasone; Rd: Lenalidomide-Dexamethasone; EloRd: Elotuzumab-Lenalidomide-Dexamethasone; IxaRd: Ixazomib-Lenalidomide-Dexamethasone. (b) Cohort of Multiple Myeloma patients treated with DVd (Daratumumab + Bortezomib + Dexamethasone): TTP in the subgroup of "Lenalidomide-refractory patients" (70.6% of patients). [Extracted from the article]